Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Biocon Pharma partners with Libbs Farmaceutica to launch generic formulations in Brazil29-03-2021
29-03-2021
Biocon Ltd - 532523 - Intimation For Incorporation Of Wholly Owned Subsidiary Company - Biofusion Therapeutics Limited.
With reference to the captioned subject, we would like to inform you that the Company has incorporated a wholly owned subsidiary company "Biofusion Therapeutics Limited' on March 18, 2021.19-03-2021
Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meeting09-03-2021
BIOCON LTD. - 532523 - Disclosure Pursuant To Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations').
Further to our intimation dated January 7, 2021, in relation to execution of a Share Subscription Agreement ('SSA') and a Shareholders' Agreement ('SHA') between Biocon Limited (the 'Company'), Biocon Biologics Limited ('BBL'), existing investors of BBL and Beta Oryx Limited, a wholly owned subsidiary of ADQ (the 'Investor') as applicable, we wish to inform you that the subscription money aggregating to ~Rs. 555 Crores have been received by BBL from the Investor. Consequently, today the Board of BBL has approved allotment of 1,97,99,305 (One Crore Ninety Seven Lakhs Ninety Nine Thousand Three Hundred Five) equity shares at face value of Rs. 10/- (Indian Rupees Ten only) each at an issue price of Rs. 280.31 (Indian Rupees Two Hundred and Eighty and Paisa Thirty One only) per share including a premium of Rs. 270.31 (Indian Rupees Two Hundred and Seventy and Paisa Thirty One only) per share to the Investor.08-03-2021
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meeting04-03-2021
Biocon Biologics appoints Susheel Umesh as Chief Commercial Officer for emerging markets
His appointment comes at a time when the company is setting up a direct commercial presence in many markets02-03-2021
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Biocon Biologics Appoints Susheel Umesh as Chief Commercial Officer for Emerging Markets02-03-2021
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Biocon Biologics Promotes Shreehas Tambe to Deputy Chief Executive Officer01-03-2021
Biocon Biologics, Viatris get CHMP nod for Abevmy
Drug is a biologic therapy for metastatic colorectal carcinoma, metastatic breast cancer, non-small-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer01-03-2021
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Biocon Biologics and Viatris Inc. Receive CHMP Nod for Abevmy(r), a Biosimilar to Avastin(r) (Bevacizumab)01-03-2021